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Context: Vaspin is an adipokine with insulin-sensitizing effects identified from visceral adipose
tissues of genetically obese rats.
Objective: We investigated genetic and nongenetic factors that define serum concentrations of
vaspin.
Design, Setting and Participants: Vaspin levels were measured with RIA in Japanese subjects with
normal fasting plasma glucose (NFG; n 259) and type 2 diabetes patients (T2D; n 275). Single
nucleotide polymorphisms (SNP) at SERPINA12 (vaspin) gene locus were discovered, and five SNP
were genotyped in the subjects with varied body mass index (n  1138).
Results:The levelof serumvaspin in93%of the sampleswas foundtovary from0.2 tonearly2ng/ml
inNFG subjects (n259) and from0.2 tonearly 3ng/ml in T2Dpatients (n275) (VaspinLowgroup),
whereas a significant subpopulation (7%) in both groups displayed much higher levels of 10–40
ng/ml (VaspinHigh group). In the VaspinLow group, serum vaspin levels in T2D were significantly
higher than healthy subjects (0.99 0.04 vs. 0.86 0.02 ng/ml; P 0.01). Both in T2D and genotyped
Japanese population, serumvaspin levels closely correlatedwith homeostasismodel of assessment for
insulin resistance rather thananthropometric parameters. Bygenotyping, rs77060950 tightly linked to
serum vaspin levels, i.e. CC (0.6 0.4 ng/ml), CA (18.4 9.6 ng/ml), andAA (30.5 5.1 ng/ml) (P 2
1016). Putative GATA-2 and GATA-3 binding consensus site was found at rs77060950.
Conclusions: Serum vaspin levels were related to insulin resistance, and higher levels of serum
vaspin in 7% of the Japanese population are closely linked to minor allele sequence (A) of
rs77060950. (J Clin Endocrinol Metab 97: E1202–E1207, 2012)
Visceral adipose tissue-derived serine proteinase in-hibitor (vaspin), SERPINA12, was identified
from visceral adipose tissues of OLETF (Otsuka Long-
Evans Tokushima Fatty) rats, which is an animal model
for obesity and type 2 diabetes (T2D) (1). The mRNA
expression of vaspin paralleled with the degree of obe-
sity and insulin resistance in OLETF rats, and the in-
jection of recombinant human vaspin into diet-induced
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obese mice ameliorated insulin resistance, indicating
that vaspin is a compensatory factor in the status of
obesity (1, 2). In humans, serum vaspin levels correlated
with body mass index (BMI) and insulin sensitivity in
adults (3–5), children (6, 7), and obese women with
polycystic ovary syndrome (8–10). Furthermore, serum
vaspin levels were decreased by weight reduction and
lifestyle modification in obese adults (11–13) and chil-
dren (6). The line of evidence supported the notion that
vaspin plays an important role in the progression of
obesity and insulin resistance.
Although many clinical reports investigating serum
vaspin levels in the patients with obesity and metabolic
syndrome are available, there are few reports investi-
gating the genetic effects on the serum vaspin levels.
Here, we measured serum vaspin levels by a wide-range
RIA system, andwe found that approximately 7%of the
population of both normal subjects and patients with
T2D demonstrated more than approximately a 10-fold
higher concentration of serum vaspin levels compared
with the rest of the population. We discovered that a
minor allele of rs77060950 in the SERPINA12 gene
was significantly associated with high serum levels of
vaspin in the Japanese population and demonstrated
that rs77060950 altered the transcriptional activity.
Subjects and Methods
Subjects and research design
Japanese subjects with normal fasting plasma glucose
(NFG; n  259; age, 36.6  0.73 yr) and patients with T2D
(n  275; age, 61.6  0.80 yr) were enrolled into this study.
Healthy volunteers with NFG, who did not take any medica-
tions for diabetes, hypertension, and/or dyslipidemia, re-
ceived annual medical health checkups for common disease
screening at the Okayama Southern Institute of Health. NFG
and T2D subjects agreed to measure serum vaspin levels. T2D
subjects were treated with oral hypoglycemic agents (n 98),
insulin treatment (n 79), or both (n 17). All recruited T2D
subjects agreed to undergo computed tomography and mea-
sure high-sensitivity C-reactive protein (hsCRP), oxidized
low-density lipoprotein (LDL), leptin, adiponectin, and vas-
pin levels.
For single nucleotide polymorphism (SNP) genotyping of the
SERPINA12 (vaspin) gene and measurement of serum vaspin
levels, we further collected 1138 Japanese subjects with various
BMI levels (male:female ratio, 470:668; age, 53.4  12.1 yr;
BMI, 27.6 kg/m2), who agreed to undergo computed tomogra-
phy examinations to measure the visceral fat area (VFA) and
subdermal fat area (SFA) (n 697). We enrolled the subjects in
three categories, i.e. normal weight (BMI  25.0 kg/m2), over-
weight (25.0  BMI  30.0 kg/m2), and obese (30.0  BMI
kg/m2). The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and was approved by
the ethical committee of Okayama University Graduate School
of Medicine, Dentistry, and Pharmaceutical Sciences (Registra-
tion numbers 20, 51, and 66), Kyoto University, and also by all
the appropriate institutional review boards.
Results
Serum vaspin levels well-correlated with insulin
resistance
T2D subjects (n  275; age, 61.6  0.80 yr) revealed
significantly higher levels of BMI, waist circumference,
systolic blood pressure, plasma glucose, total and LDL-cho-
lesterol, and lower high-density lipoprotein-cholesterol
comparedwithNFG subjects (n 259; age, 36.6 0.73
yr) (Supplemental Table 1, published on The Endo-
crine Society’s Journals Online web site at http://jcem.
endojournals.org). The measurement of vaspin levels in
NFG subjects revealed that the majority displayed vas-
pin levels less than 3 ng/ml. A minor fraction (n 18 or
6.9%) displayed much higher levels, ranging from 10 to
34 ng/ml (Fig. 1, A and B). The percentage of the pop-
ulation with such higher serum vaspin levels is also sim-
ilar in NFG subjects, and the majority displayed vaspin
levels less than 3 ng/ml; 7.2% of T2D subjects (n  20)
displayed much higher levels, ranging from 10 to 40
ng/ml (Fig. 1, C and D). By comparing the major pop-
ulation with vaspin levels less than 3 ng/ml (VaspinLow),
vaspin levels in T2D subjects were significantly higher
than NFG subjects (0.99 0.04 vs. 0.86 0.02 ng/ml;
P  0.01). Vaspin levels in T2D subjects were still signif-
icantly higher than NFG subjects (1.03 0.06 vs. 0.83
0.06 ng/ml; P 0.038) by analysis of covariance, adjust-
ing age as a covariant. In VaspinLow T2D subjects, vaspin
levels significantly correlated with BMI (R  0.193; P 
0.002), SFA (R  0.146; P  0.016), homeostasis model
of assessment for insulin resistance (HOMA-IR) (R 
0.142; P  0.022), hsCRP (R  0.128; P  0.042), and
leptin (R  0.169; P  0.019) levels, but not with VFA,
oxidized LDL, and adiponectin levels. The linear regres-
sion analysis was followed by a stepwise multiple regres-
sion analysis using serum vaspin levels as the dependent
variables to further analyze the significant predictors.Age,
gender, BMI, SFA, VFA, Log10HOMA-IR, Log10hsCRP,
andLog10leptin levelswere used as independent variables.
By stepwise analysis in model 1, only Log10HOMA-IR
independently correlated with serum vaspin levels, and
other variables demonstrating significant simple correla-
tion with serum vaspin levels did not enter the equation at
significant levels in model 2 (Supplemental Table 2).
Vaspin serum levels in VaspinHigh population are
genetically defined
We next measured serum vaspin levels in samples de-
rived from the parents of three independent VaspinHigh
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subjects. All individuals from the VaspinHigh group had
either parent with high serum vaspin levels, suggesting an
autosomal dominant or additive inheritance model (Sup-
plemental Table 3). Genomic DNA derived from three
independent VaspinHigh subjects and three independent
VaspinLow subjects was used for de novo sequencing by
IlluminaGenomeAnalyzer (SupplementalMethods). Five
novel SNP unique to the Vaspinhigh group were identified
(Fig. 1E), and we further investigated the allele frequency
of these SNP and serum vaspin levels in the Japanese sub-
jectswithvariousBMI (n1138) (SupplementalTable4).
Because we enrolled the normal, overweight, and obese
Japanese subjects, the average BMI (27.6  4.2 kg/m2)
was higher, and the sample subjects may not represent the
general population of Japan. This population consisted of
1028 subjects in the VaspinLow group and 110 subjects in
the VaspinHigh group. In the VaspinLow group, unlike
T2D, BMI and Log10hsCRP were negatively correlated
with serum vaspin levels. In contrast, Log10HOMA-IR
was positively correlated with serum vaspin levels like
T2D. In the VaspinHigh group, BMI was the independent
variable to predict the serum vaspin levels. Serum vaspin
levels were higher in women than men; however, the
above-mentioned correlations were similar in both men
and women (Supplemental Table 5).
Among five SNP, rs77060950 most accurately pre-
dicted the serum vaspin levels, i.e. CC (0.6  0.4 ng/ml),
CA (18.7 9.5 ng/ml), and AA (30.5 5.1 ng/ml) (Sup-
plemental Table 6 and Fig. 1F). The CC genotype com-
pletely matched to the VaspinLow group (n  1027), and
CA/AA genotype corresponded to the VaspinHigh group
(n  110). Thus, rs77060950 was a candidate for the
functional SNP for the transcriptional regulationof vaspin
gene expression, and SNP rs76624128 and rs7149693were
in the strong linkage disequilibriumwith rs77060950 (Sup-
plementalTable6).Suchstrong linkagewasalso true inNFG
and impaired fasting glucose/diabetes mellitus subgroups,
defined by the fasting plasma glucose levels (Supplemental
Table 7). Although serum vaspin levels were tightly associ-
atedwith rs77060950, various clinical parameters obtained
in the cross-sectional studywere not significantly different in
CC, CA, and AA genotypes of rs77060950 (Supplemental
Table 8).
We found GATA transcription factor consensus bind-
ing site around rs77060950 by TFSEARCH and MOTIF
search programs (Fig. 2A). We compared the luciferase
activities andgel shift byusing theminor (A) andmajor (C)
alleles of rs77060950 (Supplemental Methods). Lu-
ciferase activities were significantly higher in the minor
allele construct, pGL4–175A vector, compared with the
major allele construct, pGL4-175C vector (Fig. 2B). Lu-
ciferase activities were higher in pGL4-295A, pGL4-
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FIG. 1. Serum vaspin levels in the subjects with NFG and the patients
with T2D. A, A minor fraction (6.9%) of NFG (n 259) displays much
higher levels (circled), ranging from 10 to 34 ng/ml. B, The majority of
subjects displayed vaspin levels less than 2 ng/ml. C, Similarly, 7.2% of the
patients with T2D (n 275) displayed much higher levels (circled),
ranging from 10 to 40 ng/ml. D, The majority of the patients with T2D
displayed vaspin levels less than 3 ng/ml. E, The localization of five SNP
identified at SERPINA12 (vaspin) gene and linkage disequilibrium
coefficients between five SNP in the SERPINA12 gene. F, Serum vaspin
levels in the subjects with various genotypes. Among five SNP,
rs77060950 completely links the serum vaspin levels, i.e. CC (0.6 0.4
ng/ml), CA (18.4 9.6 ng/ml), and AA (30.5 5.1 ng/ml).
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375A,andpGL4-545Avectors comparedwithpGL4-295C,
pGL4-375C, and pGL4-545C vectors, respectively, al-
though they were not statistically significant. We next
tested the binding of the rs77060950 minor and major
allele sequences by GATA with EMSA and demonstrated
DNA-protein complexes using oligo (A), minor allele se-
quence, and the intensity of the complexes was much
weaker in oligo (C), major allele sequence (Fig. 2C). We
also observed no supershifting and competition for bind-
ing by the treatment of anti-GATA-1, -GATA-2, and
-GATA-3-specific antibodies in thema-
jor and minor allele sequences (Fig.
2C).
Discussion
A major finding of the current study is
that approximately 7%of the Japanese
population revealed much higher se-
rum vaspin concentrations in both
NFG and T2D subjects. Furthermore,
VaspinHigh subjects are genetically de-
fined by minor allele sequence (A) of
rs77060950. Another significant find-
ing is that serum vaspin levels closely
correlated with HOMA-IR rather than
anthropometric parameters both in
T2D subjects and the genotyped Japa-
nese population.
Such unique logarithmic normal dis-
tribution of serum vaspin concentra-
tions has not been reported in any other
serum proteins. One exception may be
the casewith lipoprotein(a), which also
demonstrates the logarithmic normal
distribution of serum concentration.
However, lipoprotein(a) is disulfide-
linked to apolipoprotein B-100, and it
contains two types of plasminogen-like
kringle domains revealed the variation
of the copy number, which resulted in
the six phenotypes with varied serum
concentration (14, 15). In contrast to
the case with lipoprotein(a), we did not
find any differences in the coding se-
quence of the SERPINA12 (vaspin)
gene in six families of VaspinHigh and
VaspinLow groups revealed by de novo
sequencing of PCR-amplified genomic
DNAs (Supplemental Methods and
Supplemental Table 9) using Illumina
Genome Analyzer, and thus the varia-
tion of serum concentrations of vaspin could not be at-
tributed to the difference of the protein structure and
half-life of vaspin protein. Based upon these consider-
ations, we speculated that serum vaspin levels are closely
linked to transcriptional activities of the SERPINA12
(vaspin) gene, which are determined by the minor allele
sequence (A) of rs77060950. Actually, minor allele se-
quence (A) of rs77060950 alters a GATA transcription
factor binding site associated with increased luciferase ac-
tivity using pGL4 construct containing 175 bp flanking
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FIG. 2. Luciferase assay and EMSA. A, In the flanking region of rs77060950, GATA
transcription factor binding site (underlined) is found, and oligos (A) and (C) were prepared
(dotted underline). B, Luciferase assay using various pGL4 constructs. Higher luciferase activity
was observed in pGL4–175A compared with pGL4–175C vector (P  0.006). C, EMSA. The
intense DNA-protein complex using oligo (A), minor allele sequence, was observed compared
with oligo (C), major allele sequence (lanes 2 and 3). The DNA-protein complex was reduced
by the addition of 100-fold excess of unlabeled oligo (A) (lane 7). The addition of anti-GATA-
1, -GATA-2, and -GATA-3 antibodies did not demonstrate supershift (lanes 4–6).
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rs77060950 and enhanced the formation ofDNA-protein
complex by EMSA compared with minor allele sequence
(C) of rs77060950. Among the GATA transcription fac-
tors, GATA-2 and GATA-3 are specifically expressed in
white adipocyte precursors, and their down-regulation
sets the stage for terminal differentiation. GATA-3-defi-
cient embryonic stem cells exhibit an enhanced capacity to
differentiate into adipocytes, and defective GATA-2 and
GATA-3 expression is associated with obesity (16). Al-
though TFSEARCH and MOTIF search programs pre-
dicted that GATA-2 andGATA-3 are good candidates for
the regulators for transcriptional activities of the SER-
PINA12 gene, the lack of supershift in EMSA by anti-
GATA-2 and -GATA-3 antibodies may suggest the pres-
ence of uncharacterized transcriptional factors that bind
to the genomic DNA region surrounding the rs77060950,
andmore intensive characterization of molecular genetics
may be required.
In a previous publication, Kempf et al. (17) reported
the significant association of vaspin SNP rs2236242
with T2D in the KORA F3 study, with the AA genotype
bearing an increased risk [adjusted odds ratio, 2.35
(1.59, 3.46) vs. AT/TT]. However, the comparison of
various clinical parameters between VaspinHigh and
VaspinLow groups revealed that only insulin resistance
index (microunits per milliliter) was higher in the AA
genotype compared with CC and CA genotypes, al-
though it did not reach statistically significant differ-
ences. The frequency of population with higher vaspin
levels of more than 10 ng/ml seems to be different in
various ethnic groups, i.e. approximately 1% in a Eu-
ropean population in previous reports (18, 19); thus,
the clinical characterization of the VaspinHigh group
may bemore difficult in a Caucasian population. Future
cohort studies enrolling the Japanese population with
higher serum vaspin levels with AA and CA genotypes
of rs77060950 are required to demonstrate susceptibil-
ities for the development of obesity, insulin resistance,
diabetes, nonalcoholic fatty liver disease, and various
vascular disorders.
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